top of page
The Sound of Evolution
Zafirlukast
Mechanism of action:
Zafirlukast is a CysLT₁ receptor antagonist. It competitively blocks the binding of leukotrienes C₄, D₄, and E₄ (LTC₄, LTD₄, and LTE₄) to the CysLT₁ receptor, thereby inhibiting leukotriene-mediated inflammation and airway constriction.
Reference(s):
1. Chen X et al. (2002). TTD: Therapeutic Target Database. Nucleic Acids Res.
2. Cazzola M et al. (2000). Lung function improvement in smokers suffering from COPD with zafirlukast, a CysLT(1)-receptor antagonist. Pulm Pharmacol Ther.
3. Murata Y et al. (2002). [Zafirlukast (Accolate): a review of its pharmacological and clinical profile]. Nihon Yakurigaku Zasshi.
bottom of page